Free Trial
Trung Huynh

Trung Huynh Analyst Performance

Equity Research - US Pharma and Biotech at UBS Group

Trung Huynh is a stock analyst at UBS Group in the medical sector, covering 8 publicly traded companies. Over the past year, Trung Huynh has issued 16 stock ratings, including buy and hold recommendations. While full access to Trung Huynh's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Trung Huynh's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
20 Last 2 Years
Buy Recommendations
50.00% 8 Buy Ratings
Companies Covered
8 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy50.0%8 ratings
Hold50.0%8 ratings
Sell0.0%0 ratings

Out of 16 total stock ratings issued by Trung Huynh at UBS Group, the majority (50.0%) have been Buy recommendations, followed by 50.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
62.5% of companies on NASDAQ
5 companies
NYSE
37.5% of companies on NYSE
3 companies

Trung Huynh, an analyst at UBS Group, currently covers 8 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
8 companies
100.0%

Trung Huynh of UBS Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
75.0%
LARGE CAP PHARMA
2 companies
25.0%

Trung Huynh's Ratings History at UBS Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
8/15/2025Lower Price Target$2.99$25.00Buy
Insmed, Inc. stock logo
INSM
Insmed
8/8/2025Boost Price Target$107.36$133.00Buy
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
8/8/2025Lower Price Target$627.50$895.00Buy
Amgen Inc. stock logo
AMGN
Amgen
8/6/2025Lower Price Target$284.05$317.00Neutral
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
8/1/2025Reiterated Rating$545.46Neutral
Amgen Inc. stock logo
AMGN
Amgen
7/21/2025Boost Price Target$296.13$326.00Neutral
Insmed, Inc. stock logo
INSM
Insmed
5/9/2025Lower Price Target$65.08$109.00Buy
Amgen Inc. stock logo
AMGN
Amgen
5/2/2025Reiterated Rating$277.09$315.00Neutral
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
5/2/2025Lower Price Target$825.10$1,050.00Buy
Pfizer Inc. stock logo
PFE
Pfizer
4/30/2025Boost Price Target$24.14$25.00Neutral
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
4/11/2025Lower Price Target$49.80$54.00Neutral
Pfizer Inc. stock logo
PFE
Pfizer
4/8/2025Lower Price Target$21.75$24.00Neutral
Insmed, Inc. stock logo
INSM
Insmed
3/6/2025Boost Price Target$75.02$110.00Buy
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2/13/2025Initiated Coverage$22.26$44.00Buy
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2/13/2025Initiated Coverage$5.49$38.00Buy
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
1/16/2025Downgrade$703.43$738.00Neutral